Join us at TNW Conference 2022 for insights into the future of tech →

The heart of tech

This article was published on January 23, 2014

Sony is focusing on advancing genetic research in Japan with its latest joint-venture

Sony is focusing on advancing genetic research in Japan with its latest joint-venture Image by: AFP/Getty Images
Jon Russell
Story by

Jon Russell

Jon Russell was Asia Editor for The Next Web from 2011 to 2014. Originally from the UK, he lives in Bangkok, Thailand. You can find him on T Jon Russell was Asia Editor for The Next Web from 2011 to 2014. Originally from the UK, he lives in Bangkok, Thailand. You can find him on Twitter, Angel List, LinkedIn.

Search giant Google last year formed a company focused on tackling aging and other associated diseases, and now Sony is upping its commitment to breakthrough medicine after it announced a joint venture focused on advancing medical research using genetics in Japan.

The organization — which is called P5 and founded by Sony and Japanese medical giant M3 — will focus on assisting medical breakthroughs using genome research, a technique to establish the origins of diseases using genetics and other data, and developing new forms of medicines and methods of treatment.

“I’m very excited by the potential of this collaboration to deliver new services and breakthroughs that bring us ever closer to the realization of the personalized medicine and healthcare era,” said Tadashi Saito, who heads up Sony’s medical business. “We aim to facilitate genome research that further advances Japanese medical care, and in the future establish a new service platform for the medical industry.”

P5, which is backed by 118.75 million Yen ($1.1 billion) in capital, is expected to launch by the end of February 2014. The organization will be headquartered in Tokyo.

Headline image via TOSHIFUMI KITAMURA/AFP/Getty Images

http://www.gettyimages.co.uk/detail/news-photo/outside-view-of-the-sony-headquarters-building-in-tokyo-on-news-photo/168372112